MedWatch

"We have the potential to reinvent Lundbeck"

If Lundbeck succeeds in developing an Alzheimer's drug, it can potentially generate a revenue comparable to the whole company's current total revenue. This is according to EVP Bjørn Grønning.

Foto: Joachim Rode

In 2016, the future looked promising for Danish drug group Lundbeck's aspirations to make the next breakthrough in the treatment of the feared dementia of the Alzheimer's type.

The company was ready with a potential candidate, the drug idalopirdine that appeared as a promising symptom management all the way to phase III.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier